(Total Views: 261)
Posted On: 03/13/2020 8:42:28 AM
Post# of 124
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
$AYTU Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today the establishment of a COVID-19 inquiry procedure to ensure the company adequately responds to inbound inquires from professionals and the public.
In order to streamline and effectively capture the significant number of inbound inquiries related to the COVID-19 IgG/IgM Rapid Test, the company requests healthcare professionals, institutions, and other interested parties to send email inquiries to a COVID-19-dedicated email address.
Inquiries should be directed via email to COVID-19@aytubio.com.
Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, "Aytu BioScience is working to be as responsive as possible to the numerous inbound inquiries we're receiving relating to the COVID-19 Rapid Test. With the high volume of inbound calls and emails the Company has received, we want to ensure effective communication and timely response to these calls and emails."
The COVID-19 IgG/IgM Rapid Test is a solid phase immunochromatographic assay used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 Novel Coronavirus in human whole blood, serum or plasma. This point-of-care test has been validated in a 113 patient clinical trial and has received CE marking. It is currently one of only a few tests used for coronavirus screening in China.
In order to streamline and effectively capture the significant number of inbound inquiries related to the COVID-19 IgG/IgM Rapid Test, the company requests healthcare professionals, institutions, and other interested parties to send email inquiries to a COVID-19-dedicated email address.
Inquiries should be directed via email to COVID-19@aytubio.com.
Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, "Aytu BioScience is working to be as responsive as possible to the numerous inbound inquiries we're receiving relating to the COVID-19 Rapid Test. With the high volume of inbound calls and emails the Company has received, we want to ensure effective communication and timely response to these calls and emails."
The COVID-19 IgG/IgM Rapid Test is a solid phase immunochromatographic assay used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 Novel Coronavirus in human whole blood, serum or plasma. This point-of-care test has been validated in a 113 patient clinical trial and has received CE marking. It is currently one of only a few tests used for coronavirus screening in China.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)